| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Cyclobenzaprine | hsa00030 | Pentose phosphate pathway | 1.08E-05 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | | | Cyclobenzaprine | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | | Cyclobenzaprine | hsa00190 | Oxidative phosphorylation | 3.92E-05 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | | Cyclobenzaprine | hsa00220 | Arginine biosynthesis | 3.83E-02 | 2 | P05089, P49448 | ARG1, GLUD2 | More | | | Cyclobenzaprine | hsa00500 | Starch and sucrose metabolism | 1.79E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Cyclobenzaprine | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | | Cyclobenzaprine | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | | Cyclobenzaprine | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | | | Cyclobenzaprine | hsa00604 | Glycosphingolipid biosynthesis - ganglio series | 2.87E-03 | 3 | P06865, O15466, Q9H4F1 | HEXA, ST8SIA5, ST6GALNAC4 | More | | | Cyclobenzaprine | hsa00730 | Thiamine metabolism | 4.66E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | | Cyclobenzaprine | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | | Cyclobenzaprine | hsa00830 | Retinol metabolism | 2.17E-03 | 4 | P00325, P00352, Q9BPW9, O75911 | ADH1B, ALDH1A1, DHRS9, DHRS3 | More | | | Cyclobenzaprine | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | | Cyclobenzaprine | hsa00970 | Aminoacyl-tRNA biosynthesis | 7.90E-03 | 3 | O95363, P54136, Q15046 | FARS2, RARS1, KARS | More | | | Cyclobenzaprine | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Cyclobenzaprine | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | | Cyclobenzaprine | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | | | Cyclobenzaprine | hsa01230 | Biosynthesis of amino acids | 2.22E-03 | 4 | P51854, P60891, Q99707, P37837 | TKTL1, PRPS1, MTR, TALDO1 | More | | | Cyclobenzaprine | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | | Cyclobenzaprine | hsa01523 | Antifolate resistance | 3.80E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | | Cyclobenzaprine | hsa02010 | ABC transporters | 2.17E-03 | 3 | P45844, P08183, Q8IZY2 | ABCG1, ABCB1, ABCA7 | More | | | Cyclobenzaprine | hsa03008 | Ribosome biogenesis in eukaryotes | 1.88E-02 | 3 | O14980, O60832, Q9BVP2 | XPO1, DKC1, GNL3 | More | | | Cyclobenzaprine | hsa03013 | RNA transport | 2.35E-05 | 10 | O14980, P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, Q14240, P23588, Q9Y6A5 | XPO1, NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF4A2, EIF4B, TACC3 | More | | | Cyclobenzaprine | hsa03020 | RNA polymerase | 4.49E-07 | 5 | P30876, P24928, P62487, Q9GZM3, P52435 | POLR2B, POLR2A, POLR2G, POLR2J2, POLR2J | More | | | Cyclobenzaprine | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | | | Cyclobenzaprine | hsa03050 | Proteasome | 1.21E-02 | 1 | P28074 | PSMB5 | More | | | Cyclobenzaprine | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | | Cyclobenzaprine | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | | Cyclobenzaprine | hsa04060 | Cytokine-cytokine receptor interaction | 5.34E-03 | 11 | P14784, P27930, P14778, P26842, Q06643, Q13651, P25024, Q9UBD3, P47992, P09341, P01730 | IL2RB, IL1R2, IL1R1, CD27, LTB, IL10RA, CXCR1, XCL2, XCL1, CXCL1, CD4 | More | | | Cyclobenzaprine | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 1.70E-03 | 8 | P09341, P19875, P25024, P25025, P47992, Q9UBD3, Q13651, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, XCL1, XCL2, IL10RA, IL2RB | More | | | Cyclobenzaprine | hsa04062 | Chemokine signaling pathway | 6.08E-06 | 15 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, P49841 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, GSK3B | More | | | Cyclobenzaprine | hsa04064 | NF-kappa B signaling pathway | 2.68E-06 | 18 | Q13489, O00463, Q13546, P14778, P01584, P19174, Q04759, Q9UDY8, P07948, P06239, P63279, P24522, Q8NHW4, P09341, P19875, Q06643, Q9UNE0, Q9NQC7 | BIRC3, TRAF5, RIPK1, IL1R1, IL1B, PLCG1, PRKCQ, MALT1, LYN, LCK, UBE2I, GADD45A, CCL4L2, CXCL1, CXCL2, LTB, EDAR, CYLD | More | | | Cyclobenzaprine | hsa04071 | Sphingolipid signaling pathway | 1.19E-02 | 4 | P21453, Q9H228, P01375, Q13362 | S1PR1, EDG8, TNF, PPP2R5C | More | | | Cyclobenzaprine | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | | Cyclobenzaprine | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | | | Cyclobenzaprine | hsa04110 | Cell cycle | 6.80E-03 | 6 | P06493, O75293, P30304, P33981, P42773, P01106 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC | More | | | Cyclobenzaprine | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | | Cyclobenzaprine | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | | Cyclobenzaprine | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | | | Cyclobenzaprine | hsa04144 | Endocytosis | 1.67E-02 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | | | Cyclobenzaprine | hsa04145 | Phagosome | 2.57E-02 | 4 | Q15080, P14598, Q13488, O60603 | NCF4, NCF1, TCIRG1, TLR2 | More | | | Cyclobenzaprine | hsa04211 | Longevity regulating pathway | 1.18E-02 | 3 | Q12778, Q9UEF7, Q96KQ7 | FOXO1, KL, EHMT2 | More | | | Cyclobenzaprine | hsa04213 | Longevity regulating pathway - multiple species | 3.67E-04 | 7 | P42338, Q9Y4H2, Q08828, P51828, P0DMV8, P11142, Q13547 | PIK3CB, IRS2, ADCY1, ADCY7, HSPA1A, HSPA8, HDAC1 | More | | | Cyclobenzaprine | hsa04217 | Necroptosis | 2.34E-05 | 13 | P01375, P01568, P48023, Q13489, Q13546, P42224, Q14765, P08238, Q6FI13, Q99878, Q93077, O43633, Q08752 | TNF, IFNA21, FASLG, BIRC3, RIPK1, STAT1, STAT4, HSP90AB1, H2AC18; H2AC19, H2AC14, HIST1H2AC, CHMP2A, PPID | More | | | Cyclobenzaprine | hsa04218 | Cellular senescence | 4.79E-02 | 4 | P01106, O75293, P30304, P06493 | MYC, GADD45B, CDC25A, CDK1 | More | | | Cyclobenzaprine | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | | | Cyclobenzaprine | hsa04270 | Vascular smooth muscle contraction | 6.96E-03 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | | Cyclobenzaprine | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | | | Cyclobenzaprine | hsa04610 | Complement and coagulation cascades | 6.23E-06 | 1 | P0C0L4 | C4A | More | | | Cyclobenzaprine | hsa04612 | Antigen processing and presentation | 9.02E-05 | 8 | P13765, P01730, Q14953, P26715, P26717, Q13241, P01732, P01375 | HLA-DOB, CD4, KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | | | Cyclobenzaprine | hsa04613 | Neutrophil extracellular trap formation | 2.15E-05 | 11 | P11215, Q13547, P04908, Q93077, P58876, P62807, Q16778, O60814, P68431, O43315, Q16539 | ITGAM, HDAC1, H2AC4; H2AC8, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | | | Cyclobenzaprine | hsa04620 | Toll-like receptor signaling pathway | 4.16E-02 | 2 | Q13546, P01568 | RIPK1, IFNA21 | More | | | Cyclobenzaprine | hsa04621 | NOD-like receptor signaling pathway | 4.72E-02 | 3 | P01568, Q13489, Q13546 | IFNA21, BIRC3, RIPK1 | More | | | Cyclobenzaprine | hsa04622 | RIG-I-like receptor signaling pathway | 2.39E-02 | 2 | P01568, Q13546 | IFNA21, RIPK1 | More | | | Cyclobenzaprine | hsa04623 | Cytosolic DNA-sensing pathway | 7.14E-06 | 5 | P01584, P01568, Q13546, P25963, Q8NHW4 | IL1B, IFNA21, RIPK1, NFKBIA, CCL4L2 | More | | | Cyclobenzaprine | hsa04640 | Hematopoietic cell lineage | 1.47E-06 | 12 | P13612, P21926, P14778, P27930, P11215, P25063, P07766, P09693, P01732, P01730, P09564, P13765 | ITGA4, CD9, IL1R1, IL1R2, ITGAM, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB | More | | | Cyclobenzaprine | hsa04650 | Natural killer cell mediated cytotoxicity | 3.96E-10 | 13 | P19174, P01375, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, Q14953, P26715 | PLCG1, TNF, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KIR2DS5, KLRC1 | More | | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
|---|
| Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P01375 | TNF | Tumor necrosis factor | -0.755 | | P06239 | LCK | Tyrosine-protein kinase Lck | P06239 | LCK | Tyrosine-protein kinase Lck | 1 | | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | | P06239 | LCK | Tyrosine-protein kinase Lck | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.906 | | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | | P06239 | LCK | Tyrosine-protein kinase Lck | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.927 | | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.727 | | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | | P06239 | LCK | Tyrosine-protein kinase Lck | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.758 | | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.838 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.886 | | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.701 | | P06239 | LCK | Tyrosine-protein kinase Lck | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.732 | | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.756 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.72 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | Q14953 | KIR2DS5 | Killer cell immunoglobulin-like receptor 2DS5 | 0.815 | | P06239 | LCK | Tyrosine-protein kinase Lck | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.756 | | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | | P07550 | ADRB2 | Beta-2 adrenergic receptor | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.72 |
| | Cyclobenzaprine | hsa04657 | IL-17 signaling pathway | 2.41E-02 | 4 | P19875, P14780, P80188, P01375 | CXCL2, MMP9, LCN2, TNF | More | | | Cyclobenzaprine | hsa04658 | Th1 and Th2 cell differentiation | 2.82E-10 | 12 | Q04759, P07766, P20963, P09693, P19174, P01730, P06239, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, PLCG1, CD4, LCK, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | | Cyclobenzaprine | hsa04659 | Th17 cell differentiation | 2.90E-08 | 12 | Q04759, P19174, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P07766, P09693, P20963 | PRKCQ, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, CD3E, CD3G, CD247 | More | | | Cyclobenzaprine | hsa04660 | T cell receptor signaling pathway | 1.36E-06 | 14 | P01375, Q04759, P42338, Q08881, P19174, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, ITK, PLCG1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | | Cyclobenzaprine | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | | | Cyclobenzaprine | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | | | Cyclobenzaprine | hsa04721 | Synaptic vesicle cycle | 3.15E-02 | 2 | Q13488, P31645 | TCIRG1, SLC6A4 | More | | | Cyclobenzaprine | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | | Cyclobenzaprine | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | | Cyclobenzaprine | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | | | Cyclobenzaprine | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | | | Cyclobenzaprine | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.85E-04 | 9 | P14778, P01584, Q08828, P51828, P19174, P42338, P24723, Q04759, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PLCG1, PIK3CB, PRKCH, PRKCQ, CALM1 | More | | | Cyclobenzaprine | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | | | Cyclobenzaprine | hsa04915 | Estrogen signaling pathway | 3.17E-02 | 5 | Q08828, P51828, P0DMV8, P0DP23, Q15788 | ADCY1, ADCY7, HSPA1A, CALM1, NCOA1 | More | | | Cyclobenzaprine | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | | Cyclobenzaprine | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | | | Cyclobenzaprine | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | | | Cyclobenzaprine | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | | | Cyclobenzaprine | hsa04932 | Non-alcoholic fatty liver disease | 7.01E-05 | 11 | P01375, P49841, O43521, P48023, O75460, P01584, P13073, P12074, Q16718, O95298, O14521 | TNF, GSK3B, BCL2L11, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFA5, NDUFC2, SDHD | More | | | Cyclobenzaprine | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Cyclobenzaprine | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | | Cyclobenzaprine | hsa04966 | Collecting duct acid secretion | 1.38E-03 | 2 | P02730, P00918 | SLC4A1, CA2 | More | | | Cyclobenzaprine | hsa04970 | Salivary secretion | 2.43E-03 | 6 | P07550, Q08828, P51828, P22694, P0DP23, P49913 | ADRB2, ADCY1, ADCY7, PRKACB, CALM1, CAMP | More | | | Cyclobenzaprine | hsa04972 | Pancreatic secretion | 1.31E-02 | 2 | Q08828, P62491 | ADCY1, RAB11A | More | | | Cyclobenzaprine | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | | Cyclobenzaprine | hsa04975 | Fat digestion and absorption | 2.80E-02 | 1 | O14494 | PLPP1 | More | | | Cyclobenzaprine | hsa04976 | Bile secretion | 3.14E-03 | 5 | O43315, Q08828, P51828, P08183, Q14032 | AQP9, ADCY1, ADCY7, ABCB1, BAAT | More | | | Cyclobenzaprine | hsa05016 | Huntington disease | 1.00E-04 | 12 | O95298, P13073, P12074, Q9GZM3, P24928, P30876, P62487, P52435, Q9NYC9, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2J2, POLR2A, POLR2B, POLR2G, POLR2J, DNAH9, ERN1, PSMB4, PSMD12 | More | | | Cyclobenzaprine | hsa05017 | Spinocerebellar ataxia | 2.43E-02 | 1 | P28074 | PSMB5 | More | | | Cyclobenzaprine | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | | | Cyclobenzaprine | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | | | Cyclobenzaprine | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | | | Cyclobenzaprine | hsa05034 | Alcoholism | 2.05E-05 | 7 | Q13547, Q93077, P58876, P62807, Q16778, O60814, P68431 | HDAC1, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Cyclobenzaprine | hsa05100 | Bacterial invasion of epithelial cells | 4.50E-02 | 1 | Q92529 | SHC3 | More | | | Cyclobenzaprine | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.62E-04 | 7 | Q16539, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | | Cyclobenzaprine | hsa05132 | Salmonella infection | 9.85E-03 | 4 | Q13546, Q13489, O60282, P68371 | RIPK1, BIRC3, KIF5C, TUBB2C | More | | | Cyclobenzaprine | hsa05133 | Pertussis | 4.24E-03 | 1 | P0C0L4 | C4A | More | | | Cyclobenzaprine | hsa05134 | Legionellosis | 8.80E-04 | 7 | P01584, Q9NR31, P11215, P0DMV8, P11142, P09341, P19875 | IL1B, SAR1A, ITGAM, HSPA1A, HSPA8, CXCL1, CXCL2 | More | | | Cyclobenzaprine | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | | Cyclobenzaprine | hsa05140 | Leishmaniasis | 5.18E-04 | 6 | P14598, P42224, O60603, P25963, P29350, Q15080 | NCF1, STAT1, TLR2, NFKBIA, PTPN6, NCF4 | More | | | Cyclobenzaprine | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | | Cyclobenzaprine | hsa05144 | Malaria | 1.12E-04 | 6 | P60033, P69905, P68871, P01375, P35443, P26718 | CD81, HBA2, HBB, TNF, THBS4, KLRK1 | More | | | Cyclobenzaprine | hsa05146 | Amoebiasis | 7.67E-07 | 12 | P09341, P19875, P14778, P27930, P01375, P42338, P11215, P05089, P30679, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, PIK3CB, ITGAM, ARG1, GNA15, PRKACB, ACTN1, CTSG | More | | | Cyclobenzaprine | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | | Cyclobenzaprine | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | | Cyclobenzaprine | hsa05163 | Human cytomegalovirus infection | 1.80E-03 | 15 | P01375, P63218, P50151, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, O00463 | TNF, GNG5, GNG10, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, TRAF5 | More | | | Cyclobenzaprine | hsa05168 | Herpes simplex virus 1 infection | 3.38E-03 | 12 | P25963, P01568, Q05823, P42224, Q07955, Q13243, Q13489, Q13398, Q9HCX3, P52738, O75820, Q9UDV6 | NFKBIA, IFNA21, RNASEL, STAT1, SFRS1, SFRS5, BIRC3, ZNF211, ZNF304, ZNF140, ZNF189, ZNF212 | More | | | Cyclobenzaprine | hsa05169 | Epstein-Barr virus infection | 4.84E-03 | 10 | P13765, P01106, Q13547, O00463, P07948, Q13761, P24522, P07766, P09693, P20963 | HLA-DOB, MYC, HDAC1, TRAF5, LYN, RUNX3, GADD45A, CD3E, CD3G, CD247 | More | | | Cyclobenzaprine | hsa05202 | Transcriptional misregulation in cancer | 1.24E-02 | 4 | P27930, P11215, Q13547, P12980 | IL1R2, ITGAM, HDAC1, LYL1 | More | | | Cyclobenzaprine | hsa05203 | Viral carcinogenesis | 1.22E-03 | 6 | Q13547, Q15283, P58876, P62807, Q16778, O60814 | HDAC1, RASA2, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12 | More | | | Cyclobenzaprine | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | | Cyclobenzaprine | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | | | Cyclobenzaprine | hsa05216 | Thyroid cancer | 3.80E-02 | 2 | P01106, O75293 | MYC, GADD45B | More | | | Cyclobenzaprine | hsa05218 | Melanoma | 1.07E-02 | 3 | P09619, Q9GZP0, Q02750 | PDGFRB, PDGFD, MAP2K1 | More | | | Cyclobenzaprine | hsa05223 | Non-small cell lung cancer | 1.39E-02 | 3 | P10826, Q9HC35, O75293 | RARB, EML4, GADD45B | More | | | Cyclobenzaprine | hsa05231 | Choline metabolism in cancer | 9.39E-03 | 4 | Q02750, P09619, Q9GZP0, O15245 | MAP2K1, PDGFRB, PDGFD, SLC22A1 | More | | | Cyclobenzaprine | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 9.97E-06 | 9 | P42338, P19174, P07766, P20963, P09693, P06239, Q04759, Q9HC35, P01730 | PIK3CB, PLCG1, CD3E, CD247, CD3G, LCK, PRKCQ, EML4, CD4 | More | | | Cyclobenzaprine | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | | | Cyclobenzaprine | hsa05322 | Systemic lupus erythematosus | 4.80E-06 | 7 | P09871, Q93077, P58876, P62807, Q16778, O60814, P68431 | C1S, HIST1H2AC, H2BC5, HIST1H2BC, HIST2H2BE, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | | Cyclobenzaprine | hsa05323 | Rheumatoid arthritis | 2.00E-02 | 3 | Q13488, P10747, O60603 | TCIRG1, CD28, TLR2 | More | | | Cyclobenzaprine | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | | Cyclobenzaprine | hsa05332 | Graft-versus-host disease | 9.47E-05 | 5 | P13765, P48023, P01375, P26715, Q13241 | HLA-DOB, FASLG, TNF, KLRC1, KLRD1 | More | | | Cyclobenzaprine | hsa05340 | Primary immunodeficiency | 1.31E-04 | 5 | P01730, P01732, P11912, P07766, P06239 | CD4, CD8A, CD79A, CD3E, LCK | More | | | Cyclobenzaprine | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 5.12E-03 | 3 | Q8IZS8, P54284, P13612 | CACNA2D3, CACNB3, ITGA4 | More | | | Cyclobenzaprine | hsa05414 | Dilated cardiomyopathy | 2.11E-02 | 4 | Q8IZS8, P54284, P13612, P26678 | CACNA2D3, CACNB3, ITGA4, PLN | More | | | Cyclobenzaprine | hsa05415 | Diabetic cardiomyopathy | 4.54E-04 | 8 | P17252, P14598, Q15080, Q16718, O14521, Q16539, P49841, P04406 | PRKCA, NCF1, NCF4, NDUFA5, SDHD, MAPK14, GSK3B, GAPDH | More | | | Cyclobenzaprine | hsa05418 | Fluid shear stress and atherosclerosis | 3.61E-02 | 6 | Q16539, P10599, P14780, P01375, P14778, P27930 | MAPK14, TXN, MMP9, TNF, IL1R1, IL1R2 | More | |
|
